These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33441889)

  • 1. Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease.
    Hernadi G; Pinter D; Nagy SA; Orsi G; Komoly S; Janszky J; Kovacs N; Perlaki G
    Sci Rep; 2021 Jan; 11(1):1179. PubMed ID: 33441889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.
    Zhao XJ; Niu XY; You HY; Zhou M; Ji XB; Liu Y; Wu L; Ding XL
    Curr Med Sci; 2019 Oct; 39(5):831-835. PubMed ID: 31612404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism.
    Reiter E; Mueller C; Pinter B; Krismer F; Scherfler C; Esterhammer R; Kremser C; Schocke M; Wenning GK; Poewe W; Seppi K
    Mov Disord; 2015 Jul; 30(8):1068-76. PubMed ID: 25773707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mahlknecht P; Krismer F; Poewe W; Seppi K
    Mov Disord; 2017 Apr; 32(4):619-623. PubMed ID: 28151553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity.
    Bae YJ; Song YS; Choi BS; Kim JM; Nam Y; Kim JH
    Eur J Radiol; 2021 Jan; 134():109398. PubMed ID: 33264728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With (123) I-FP-CIT SPECT.
    Bae YJ; Kim JM; Kim E; Lee KM; Kang SY; Park HS; Kim KJ; Kim YE; Oh ES; Yun JY; Kim JS; Jeong HJ; Jeon B; Kim SE
    Mov Disord; 2016 May; 31(5):684-92. PubMed ID: 26990970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.
    Kim PH; Lee DH; Suh CH; Kim M; Shim WH; Kim SJ
    Eur Radiol; 2021 Aug; 31(8):6342-6352. PubMed ID: 33449183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder.
    De Marzi R; Seppi K; Högl B; Müller C; Scherfler C; Stefani A; Iranzo A; Tolosa E; Santamarìa J; Gizewski E; Schocke M; Skalla E; Kremser C; Poewe W
    Ann Neurol; 2016 Jun; 79(6):1026-30. PubMed ID: 27016314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T.
    Schwarz ST; Afzal M; Morgan PS; Bajaj N; Gowland PA; Auer DP
    PLoS One; 2014; 9(4):e93814. PubMed ID: 24710392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Nigrosome-1 Sign Identification via Interpretable AI using True Susceptibility Weighted Imaging.
    Wang C; He N; Zhang Y; Li Y; Huang P; Liu Y; Jin Z; Cheng Z; Liu Y; Wang Y; Zhang C; Haacke EM; Chen S; Yan F; Yang G
    J Magn Reson Imaging; 2024 Nov; 60(5):1904-1915. PubMed ID: 38236577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential involvement of nigral subregions in idiopathic parkinson's disease.
    Sung YH; Lee J; Nam Y; Shin HG; Noh Y; Shin DH; Kim EY
    Hum Brain Mapp; 2018 Jan; 39(1):542-553. PubMed ID: 29064601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra.
    Liu XL; Yang LQ; Liu FT; Wu PY; Zhang Y; Zhuang H; Shi YH; Wang J; Geng DY; Li YX
    BMC Neurol; 2020 Jun; 20(1):262. PubMed ID: 32605601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.